Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.45 |
| ▸ | LPL | P06858 | 11/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311872 | 0.83 | CA1 (0.55) | CA1CA2CA9LIPGLPL | |
| SCHEMBL3451073 | 0.82 | LIPG (0.42) | CA1CA2CA9LIPGLPL | |
| SCHEMBL21612867 | 0.79 | CA1 (0.35) | CA1CA2CA9AAK1 | |
| SCHEMBL14782605 | 0.76 | MAPT (0.59) | CA1CA2CA9LIPGLPL | |
| SCHEMBL12261115 | 0.76 | LIPG (0.48) | CA1CA2CA9LIPGLPL | |
| SCHEMBL2730662 | 0.75 | CA1 (0.58) | CA1CA2CA9LIPGLPL | |
| SCHEMBL28811198 | 0.75 | CA1 (0.54) | CA1CA2CA9LIPGLPL | |
| SCHEMBL5243207 | 0.75 | CA1 (0.61) | CA1CA2CA9LIPGLPL | |
| SCHEMBL18124825 | 0.74 | CA1 (0.53) | CA1CA2CA9LIPGLPL | |
| SCHEMBL228212 | 0.74 | LPL (0.71) | CA1CA2CA9LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CA1 3580/4885CA2 1976/4885CA9 1278/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | CA1 2968/4885CA2 3263/4885CA9 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.